Phase i study of sunitinib and irinotecan for patients with recurrent malignant glioma

بواسطة David A. Reardon, James J. Vredenburgh, April Coan, Annick Desjardins, Katherine B. Peters, Sridharan Gururangan, Sith Sathornsumetee, Jeremy N. Rich, James E. Herndon, Henry S. Friedman
منشور في 2018

Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients

بواسطة David A. Reardon, James E. Herndon, Katherine Peters, Annick Desjardins, April Coan, Emil Lou, Ashley Sumrall, Scott Turner, Sith Sathornsumetee, Jeremy N. Rich, Susan Boulton, Eric S. Lipp, Henry S. Friedman, James J. Vredenburgh
منشور في 2018

Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma

بواسطة David A. Reardon, Annick Desjardins, James J. Vredenburgh, James E. Herndon, April Coan, Sridharan Gururangan, Katherine B. Peters, Roger McLendon, Sith Sathornsumetee, Jeremy N. Rich, Eric S. Lipp, Dorothea Janney, Henry S. Friedman
منشور في 2018

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

بواسطة Sith Sathornsumetee, Annick Desjardins, James J. Vredenburgh, Roger E. McLendon, Jennifer Marcello, James E. Herndon, Alyssa Mathe, Marta Hamilton, Jeremy N. Rich, Julie A. Norfleet, Sridharan Gururangan, Henry S. Friedman, David A. Reardon
منشور في 2018

Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma

بواسطة David A. Reardon, James J. Vredenburgh, Annick Desjardins, Katherine B. Peters, Sith Sathornsumetee, Stevie Threatt, John H. Sampson, James E. Herndon, April Coan, Frances McSherry, Jeremy N. Rich, Roger E. McLendon, Steven Zhang, Henry S. Friedman
منشور في 2018